Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

The Lancet

Volumn 345, Issue 8941, 1995, Pages 9-13

  Rooney, C M ^a,b   Ng, C Y C ^a   Loftin, S ^a   Smith, C A ^a   Li, C ^a   Krance, R A ^a,b   Brenner, M K ^a,b,b   Heslop, H E ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ALLOGRAFT; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CELL TRANSPLANTATION; CHILD; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; LEUKOCYTE; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; T LYMPHOCYTE; VIRUS REACTIVATION;

EID: 0028816546     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(95)91150-2     Document Type: Article

References (29)

1. Epstein-Barr virus infections biology pathogenesis and management
2. Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein Barr virus
3. Epstein-Barr virus in Lymphomas: a review
4. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency
5. Epstein-Barr virus strategy in normal and neoplastic B cells
6. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogenic bone marrow transplantation
7. Donor T cells as therapy for EBV lymphoproliferation post bone marrow transplant
8. Administration of neomycin resistance gene marked EBV specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts
9. Long-term cell-mediated immunity to Epstein-Barr virus
10. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients
11. Sub types of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma
12. Geographical prevalence of two types of Epstein-Barr virus
13. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease
14. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody response are associated with the development of post-transplant lymphoproliferative disease in solid-organ transplant recipients
15. Epstein-Barr infection after bone marrow transplantation
16. Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients
17. Donor leucocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant recipients
18. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse
19. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.
20. Epstein-Barr virus infection and immunity in bone marrow transplant recipients
21. Bone marrow transplant recipients have defective MHC-unrestricted cytotooxic response against cytomegalovirus in comparison with Epstein-Barr virus: the importance of target cell expression of lymphocyte function-associated antigen 1 (LFA1)
22. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliverative syndrome following bone marrow and organ transplantation
23. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies
24. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development
25. Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes
26. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease
27. Using T cells to treat B-cell cancers
28. Epstein-Barr virus, lymphomas and Hodgkin's disease